sibutramine has been researched along with Disease Exacerbation in 1 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clark, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bioenergetic Remodeling in the Pathophysiology and Treatment of Non-Alcoholic Liver Disease[NCT03354247] | 100 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sibutramine and Disease Exacerbation
| Article | Year |
|---|---|
Weight loss as a treatment for nonalcoholic fatty liver disease.
Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Chronic Disease; Cyclobutanes; Diet, R | 2006 |